https://www.live-feeds.com/feed/ozempic-maker-novo-nordisk-s-investors-are-nervously-looking-into-the-futureContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/ozempic-maker-novo-nordisk-s-investors-are-nervously-looking-into-the-futurehttps://www.live-feeds.com/feed/ozempic-maker-novo-nordisk-s-investors-are-nervously-looking-into-the-future#u56682Fri, 04 Sep 2026 07:55:39 +0000Investors in Ozempic maker Novo Nordisk are increasingly nervous about the future as rivals close in on the company's position in the obesity and GLP-1 drug market. The competitive landscape is growing more crowded, raising questions about whether products like CagriSema can help close the gap with competitors such as LLY. Market research points to a strong 41 percent compound annual growth rate outlook for weight loss drugs through 2030, intensifying pressure on existing market leaders to maintain their standing amid mounting competition from multiple directions.Why it mattersNovo Nordis